Résztvevőt keres2. fázis
A randomized trial comparing efficacy and safety of etanercept and methotrexate in giant cell arteritis (EFFECTA)
A legfontosabb adatok
- Ki végzi
- Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
- Hol
- Lengyelország6 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 88 fő, tervezett
- Kezdés
- 2025. márc. 12.
- Várható befejezés
- 2028. nov. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2026. február 24.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people aged 50 or older with active giant cell arteritis (GCA). It compares etanercept with methotrexate for keeping the disease quiet without steroids.
- Életkor
- 50 years and older (the record lists 18 years as the minimum, but the criteria require age ≥ 50 years).
- Nem
- All sexes can join.
- A betegség stádiuma
- Active GCA that is new, refractory (not responding to treatment) or relapsing. Symptoms must come from the disease, with ESR ≥ 30 mm/1 hour or CRP ≥ 10 mg/L at screening or within 8 weeks before.
- Korábbi kezelés
- No oral steroids above 60 mg/day prednisone and no steroids by injection or drip within 2 weeks. No methotrexate, TNFα inhibitors or similar drugs within 12 weeks. No cyclophosphamide, immunoglobulins or plasmapheresis within 6 months. No anti-CD20 antibodies within 12 months. No long-term steroids for other reasons.
- Biomarker vagy leletérték
- Raised inflammation markers: ESR ≥ 30 mm/1 hour or CRP ≥ 10 mg/L.
A részvétel fő kizáró okai
- Reduced blood flow to vital organs caused by GCA, or serious heart disease, stroke or heart attack within 6 months
- Cancer within 5 years, with a few skin and cervical exceptions
- Hepatitis B, hepatitis C, HIV or tuberculosis test positive, or severe liver or kidney problems
- Pregnancy, breastfeeding or planning either during the study
- Past major organ transplant, demyelinating disease or other autoimmune rheumatic disease
A regiszter feltételei, szó szerint
Mind a 30 feltétel megnézéseKevesebb
Ki vehet részt
- Patient’s written informed consent to participate in the study
- Age ≥ 50 years
- Diagnosis of GCA according to 2022 American College of Rheumatology/EULAR classification criteria for GCA or, in the case of involvement of only extracranial arteries, patients with a diagnosis of GCA based on medium or large-sized arterities that occurred at the age of ≥ 50 years and was confirmed by imaging, i.e. ultrasound, CT, MRI, conventional angiography or PET-CT, at the time of screening or in the past
- New onset, refractory or relapsing GCA
- Active GCA, defined as the presence of symptoms or signs attributed to GCA and not related to prior damage and elevated inflammatory markers, i.e. ESR ≥ 30 mm/1 hour or CRP ≥ 10 mg/L attributed to active GCA at screening or within 8 weeks prior to screening
- Women of child-bearing potential and men who are sexually active with a woman of child-bearing potential must agree to the use of contraception with an adequate level of effectiveness during treatment with methotrexate/etanercept and for at least 6 months after its completion
Ki nem vehet részt
- Moderate or severe heart failure (New York Heart Association class III or IV), unstable ischemic heart disease, a stroke or myocardial infarction within 6 months prior to screening, or other cardiovascular disease that, in the Investigator’s opinion, would expose the patient to an unacceptable risk in case of participation in the study
- A malignancy within 5 years prior to screening, except for: a. A completely resected cervical carcinoma in situ with no signs of recurrence within 12 months prior to screening; b. A completely cured basal cell skin carcinoma with no signs of recurrence within 12 months prior to screening
- Previous use of the following treatment: a. Within 2 weeks prior to randomization: oral corticosteroids (CS) >60 mg/day prednisone or equivalent, parenteral CS; b. Within 12 weeks prior to randomization: methotrexate, leflunomide, sulfasalazine, chloroquine, hydroxychloroquine, azathioprine, cyclosporine A, mycophenolate mofetil, TNFα inhibitors, anakinra, abatacept, IL-17 blockers; c. Within 6 months prior to randomization: immunoglobulins, plasmapheresis, cyclophosphamide or other alkylating agents; d. Within 12 months prior to randomization: anti-CD20 antibodies; e. Oral or parenteral CS used chronically for reasons other than GCA
- Abuse or addiction to drugs, alcohol or psychoactive substances
- Live/attenuated vaccinations within 3 months prior to screening or planned administration of live vaccination during the study period
- Use of other investigational drugs within 12 weeks or 5 half-lives, whichever is longer, prior to screening
- Major surgery within 3 months prior to screening or major surgery planned during the study period
- Presence of ischemia of organ important for the patient’s survival (e.g. central nervous system, heart, lungs, kidneys, alimentary tract) in the course of GCA
- Severe renal impairment
- Other severe disease (including, but not limited to, respiratory, nervous, endocrine, digestive, urinary tract disease) for which, in the Investigator’s opinion, participating in the study would expose patient to an unacceptable risk
- Presence or history of other chronic autoimmune rheumatic disease that could interfere with the evaluation of the results of the following study, including: systemic lupus erythematosus, rheumatoid arthritis, or other systemic connective tissue disease, other than GCA systemic vasculitis
- Active stomach or duodenal ulcer
- Presence or history of demyelinating syndrome
- History of major organ transplant (kidneys, lungs, heart, liver)
- Hypersensitivity to methotrexate, etanercept or any other excipients of the methotrexate or etanercept
- Acute, recurrent or chronic infection (e.g. tuberculosis, HIV infection) for which, in the Investigator’s opinion, participating in the study would expose patient to an unacceptable risk
- The following abnormalities in laboratory tests at screening: a. WBC < 3 G/L; b. NEU < 1 G/L; c. HGB < 9 g/dL; d. PLT < 100 G/L; e. ALT > 2 x ULN; f. AST > 2 x ULN; g. Total bilirubin >1,5 x ULN; h. eGFR < 50ml/min/1,73 m2; i. positive HBsAg; j. positive anti-HBc (total); k. positive anti-HCV; l. positive anti-HIV; m. positive or equivocal Quantiferon-TB Gold test
- Severe liver dysfunction
- Bone marrow hypoplasia
- Positive result of a pregnancy test performed in women of child-bearing potential at screening or Visit 1
- Pregnancy or planned pregnancy during the study
- Breastfeeding or planned breastfeeding during the study
- Lack of patient cooperation
- Oral mucous ulcers
Ez a vizsgálat jelenleg itt érhető el: Lengyelország.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To compare the effectiveness of treatment with etanercept (ETN) versus methotrexate (MTX) in the induction of sustained steroid-free remission in patients with giant cell arteritis (GCA).
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. február 24.